{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/mi-secondary-prevention/management/secondary-prevention/","result":{"pageContext":{"chapter":{"id":"6854ca49-f0af-50f1-8fd3-a6bb900b4bc4","slug":"secondary-prevention","fullItemName":"Scenario: Secondary prevention","depth":2,"htmlHeader":"<!-- begin field 61d1087e-a3ae-4235-86f4-2bbfa2c27e44 --><h2>Scenario: Secondary prevention following a myocardial infarction</h2><!-- end field 61d1087e-a3ae-4235-86f4-2bbfa2c27e44 -->","summary":"Covers recommendations on lifestyle, rehabilitation and drug treatments, and advice on managing ACE inhibitors, antiplatelet drugs, beta-blockers and statins for people following an MI but who do not have heart failure or ventricular systolic dysfunction.","htmlStringContent":"<!-- begin item 968939d0-5256-4fdf-aef2-0e42c60edd12 --><!-- begin field 68186de3-1be6-4613-9263-acbc015b7d2e --><p>From age 16 years onwards.</p><!-- end field 68186de3-1be6-4613-9263-acbc015b7d2e --><!-- end item 968939d0-5256-4fdf-aef2-0e42c60edd12 -->","topic":{"id":"10808f6c-5a83-5526-84e2-5998dee92475","topicId":"0b3a22ee-885a-43aa-8d4b-a290dc2afbcc","topicName":"MI - secondary prevention","slug":"mi-secondary-prevention","lastRevised":"Last revised in May 2020","chapters":[{"id":"6d17bc7f-3ed1-5a79-b4f4-8e9dc752c658","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"a57b961c-8bba-5c02-8844-b6307b89222c","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"dc552ddd-7106-5f5f-a7d9-4b2d6f80e1fa","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"e9a32a50-5bdc-5fc0-8ecb-152881ffa7ad","slug":"changes","fullItemName":"Changes"},{"id":"d4c6dcc6-12c6-52a1-957d-47a931a225ec","slug":"update","fullItemName":"Update"}]},{"id":"8c06d36f-1d73-5741-981b-5ed3cc16b7c2","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"cd13560d-8bec-5902-9a9e-2ce26eaa9028","slug":"goals","fullItemName":"Goals"},{"id":"b9d35945-0a30-523a-9ded-6a2ea7f5a79a","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"5c84a4ff-a034-50b3-b1a3-7cfecfb1e65c","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"02b0b701-c0f0-542f-b958-8d30a81301fc","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"f516bbb5-ea19-5f8f-be12-d8f550493156","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"cf211bbf-df50-54c9-b204-ef227db8c62f","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"3ddc8181-0420-5ae4-8326-2d5ef700203a","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"f303e07d-da7d-5073-b00b-f3dd008f2594","slug":"definition","fullItemName":"Definition"},{"id":"45810734-c13c-5bbd-b314-88dcbfd54c57","slug":"prevalence","fullItemName":"Prevalence"},{"id":"5488a58d-1964-5d60-a54e-a420fd0daeff","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"b05c9d6f-fae2-5624-bc64-e5456fa46e84","slug":"complications-prognosis","fullItemName":"Complications and prognosis"}]},{"id":"2dd1d8e3-398b-5765-b249-43150874e311","fullItemName":"Management","slug":"management","subChapters":[{"id":"6854ca49-f0af-50f1-8fd3-a6bb900b4bc4","slug":"secondary-prevention","fullItemName":"Scenario: Secondary prevention"}]},{"id":"a4fb09c9-df2a-5800-954a-58fe23af6127","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"e43e8d70-7611-5939-94cb-7cc18a3950a6","slug":"ace-inhibitors","fullItemName":"ACE inhibitors"},{"id":"0220c0cb-0802-5bfa-9d8b-f767f73dbea1","slug":"antiplatelet-treatments","fullItemName":"Antiplatelet treatments"},{"id":"a6c13387-db91-5f87-9795-c95a1be0a245","slug":"beta-blockers","fullItemName":"Beta blockers"},{"id":"064bc21b-4d02-5987-9c23-08b1ca8870d1","slug":"statins","fullItemName":"Statins"}]},{"id":"05c20737-02bb-500e-b3e6-0a506d19e727","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"1ae6e3bc-f751-5c4b-a14d-09c72b74424e","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"a3e487f8-13d0-532b-b16f-d448106af2ac","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"03c8dfe8-3b8b-5c16-ab71-21f98aa13dcd","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"a1919ef1-18db-59ab-8c6d-7ef4d649f5d3","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"3e57d884-d476-55de-a85c-a5e4e2001343","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"e8c5059d-6ccf-58a3-bb80-1a8273c64c14","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"bcfd412e-e461-5a99-a38f-a03a01873fa5","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"2dd1d8e3-398b-5765-b249-43150874e311","slug":"management","fullItemName":"Management"},"subChapters":[{"id":"25329034-ca17-52ad-a542-f9d5a4fa7b98","slug":"management","fullItemName":"Management","depth":3,"htmlHeader":"<!-- begin field 62b4d2cf-b40f-4a28-8961-481cc9793ef8 --><h3>How should I manage a person who has had a myocardial infarction?</h3><!-- end field 62b4d2cf-b40f-4a28-8961-481cc9793ef8 -->","summary":null,"htmlStringContent":"<!-- begin item b10732b4-f070-412b-ab8b-2f9737285547 --><!-- begin field 56e2c627-b107-4898-994c-a781012cde6e --><p><strong>Note: </strong>much of the advice detailed below will have already been offered to a person who has had a myocardial infarction (MI) while in hospital, during initial cardiac rehabilitation. The main role of a primary care practitioner is therefore to reinforce this advice and to encourage continued participation in cardiac rehabilitation, as well as to continue prescribing medication that was initiated by a specialist as part of any ongoing shared care arrangement.</p><ul><li><strong>Advise that relevant lifestyle changes can reduce the risk of having further cardiovascular events.</strong></li><li><strong>Advise smokers to stop and non-smokers to avoid passive smoking. </strong>Options to aid smoking cessation include referral to an NHS Stop Smoking Service, drug treatment (nicotine replacement therapy, bupropion, or varenicline), and written supporting material. For further information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/smoking-cessation/\">Smoking cessation</a>.</li><li><strong>Advise the person to adopt a cardioprotective diet. This includes:</strong><ul><li>Minimizing intake of foods containing refined sugars, including fructose.</li><li>Keeping salt intake low (less than 6 g per day). Therefore, not adding salt at the table and keeping processed foods to a minimum.</li><li>Choosing wholegrain varieties of cereals, breads, and other starchy foods.</li><li>Eating at least 4 to 5 portions per week of a mixture of unsalted nuts and seeds. (One portion is about 30 g).</li><li>Eating at least two portions of fish per week, including oily fish if the person wishes (pregnant women should limit their oily fish intake to no more than two portions per week, and avoid marlin, shark, and swordfish which may contain relatively high levels of methylmercury).</li><li>Eating at least five portions of fruits and vegetables per day.</li><li>Using olive oil or rapeseed oil for spreads, salad dressings, cooking, baking, and other food preparation rather than animal-based fats such as butter.</li><li>Advising that total fat intake should be 30% or less of total energy intake, and saturated fat (which is mainly from animal sources) should be 7% or less.</li><li>Dietary supplements including omega-3 capsules or supplemented foods are <em>not r</em>ecommended as there is no good evidence that they reduce CVD risk.</li><li>See the <a data-hyperlink-id=\"2b4f26da-d3be-4d78-af9c-aa1400a70435\" href=\"https://www.nhs.uk/live-well/eat-well/\">NHS website</a> for further practical advice. Also, consider offering a consultation specifically to discuss current diet, any improvements that can be made, and, ideally, advice that can be extended to the whole family.</li></ul></li><li><strong>Advise the person to be physically active and to avoid prolonged sedentary behaviour:</strong><ul><li>Advise them to exercise regularly, in order to increase exercise capacity. Ideally, this should be part of a comprehensive exercise based cardiac rehabilitation programme.</li><li>Exercise advice should take into account the person's current and past activity levels, comorbidities, personal circumstances, and preferences.<ul><li>In general, the aim is at least 150 minutes per week of moderate-intensity aerobic activity (to the point of slight breathlessness). Some moderate intensity activities can be incorporated into everyday life and include brisk walking, using stairs, and cycling. </li><li>Advise people to do muscle‑strengthening activities on 2 or more days a week that work all major muscle groups (legs, hips, back, abdomen, chest, shoulders and arms) in line with national guidance for the general population (for more details, see the <a data-hyperlink-id=\"84923ddc-322e-48c4-aca1-aa1400b3eb33\" href=\"https://www.nhs.uk/live-well/exercise/\">NHS website</a>).</li><li>Encourage people who are unable to perform moderate‑intensity physical activity to exercise at their maximum safe capacity and increase the duration and intensity of activity as fitness improves.</li><li>Consider referral to a qualified professional for individually tailored advice.</li></ul></li></ul></li><li><strong>Advise weight loss if the person is overweight or obese:</strong><ul><li>If obese, also assess for symptoms of sleep apnoea, and treat if appropriate.</li><li>For more information, see the CKS topics on <a class=\"topic-reference external-reference\" href=\"/topics/obesity/\">Obesity</a> and <a class=\"topic-reference external-reference\" href=\"/topics/obstructive-sleep-apnoea-syndrome/\">Obstructive sleep apnoea syndrome</a>.</li></ul></li><li><strong>Advise the person to keep alcohol consumption within the recommended limits (14 units a week for both males and females). </strong>Also, advise people who drink as much as 14 units per week that they should spread this evenly over 3 days or more.<ul><li><strong>One unit of alcohol is roughly equivalent to:</strong><ul><li>Half a pint of low/average strength beer, lager, or cider (around 3% ABV).</li><li>A small pub measure (25 mL) of spirits (40% ABV).</li><li>A standard pub measure (50 mL) of fortified wine, for example, sherry or port (20% ABV).</li></ul></li><li>If you suspect the person is misusing alcohol, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/alcohol-problem-drinking/\">Alcohol - problem drinking</a> for advice on management.</li></ul></li><li><strong>Ensure that all people who have had an MI have been offered a cardiac rehabilitation programme with exercise, health education, and stress management components, and encourage participation:</strong><ul><li>This is normally initiated in hospital before discharge, after which the person should be invited to attend a first post-discharge session that occurs within 10 days of discharge. Further sessions are then organized thereafter.</li><li>Explain to the person the benefits of attending cardiac rehabilitation. Where appropriate, discuss with the person any factors that might stop them attending a cardiac rehabilitation programme, such as transport difficulties. </li></ul></li><li><strong>If formal cardiac rehabilitation remains impractical or is declined:</strong><ul><li>Ask the person to consider the use of a home-based rehabilitation programme (such as <a data-hyperlink-id=\"35ffc563-e09a-4422-b4ca-a991002e251f\" href=\"http://www.theheartmanual.com/Pages/default.aspx\">www.theheartmanual.com</a>, a validated, home-based rehabilitation programme in both book and digital formats, for people Post-MI and/or post-revascularisation).</li><li>Offer written materials to support appropriate lifestyle advice.</li><li>Offer information regarding local and national patient support groups.</li></ul></li><li><strong>Be aware of the wider health and social care needs of a person who has had an MI. Offer information and sources of help on:</strong><ul><li>Economic issues.</li><li>Welfare rights.</li><li>Housing and social support issues.</li></ul></li><li><strong>If you suspect that the person may have anxiety or depression, </strong>see the CKS topics on <a class=\"topic-reference external-reference\" href=\"/topics/depression/\">Depression</a> and <a class=\"topic-reference external-reference\" href=\"/topics/generalized-anxiety-disorder/\">Generalized anxiety disorder</a> for advice on diagnosis and management. For management of other common comorbidities, see the CKS topics on <a class=\"topic-reference external-reference\" href=\"/topics/angina/\">Angina</a>, <a class=\"topic-reference external-reference\" href=\"/topics/hypertension-not-diabetic/\">Hypertension - not diabetic</a>, and <a class=\"topic-reference external-reference\" href=\"/topics/diabetes-type-2/\">Diabetes - type 2</a>.</li><li><strong>Ask/reassure the person about any <a class=\"topic-reference internal-reference\" href=\"/topics/mi-secondary-prevention/management/secondary-prevention/#common-concerns\">concerns</a> they may have relating to returning to work, resuming normal activities etc.</strong></li><li><strong>Continue prescribing medications that were initiated in secondary care as part of any agreed shared care arrangement:</strong><ul><li>People who have had an acute MI should generally have been offered treatment with an ACE (angiotensin-converting enzyme) inhibitor, dual antiplatelet therapy (aspirin plus a second antiplatelet agent [clopidogrel or ticagrelor]), a beta-blocker, and a statin.</li><li>The specialist in charge of the person's care should have provided a clear management plan, including details and timing of any further drug titration, and monitoring of blood pressure and renal function.</li><li>For further information, see the section on <a class=\"topic-reference internal-reference\" href=\"/topics/mi-secondary-prevention/prescribing-information/\">Prescribing information</a>.</li></ul></li><li><strong>Ensure that the following routine post-MI assessments have been arranged by secondary care:</strong><ul><li>An assessment of left ventricular function. For further information about left ventricular dysfunction and heart failure, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/heart-failure-chronic/\">Heart failure - chronic</a>.</li><li>An assessment of bleeding risk (usually at a first follow-up hospital appointment post-MI).</li><li>A cardiological assessment to consider whether coronary revascularization is appropriate.</li></ul></li><li><strong>Advise the person to have an annual influenza immunization.</strong> For further information, see the CKS topic <a class=\"topic-reference external-reference\" href=\"/topics/immunizations-seasonal-influenza/\">Immunizations - seasonal influenza</a>.</li></ul><!-- end field 56e2c627-b107-4898-994c-a781012cde6e --><!-- end item b10732b4-f070-412b-ab8b-2f9737285547 -->","subChapters":[{"id":"46a75384-abc8-598c-bdbd-261c2f4e4920","slug":"common-concerns","fullItemName":"Common concerns","depth":4,"htmlHeader":"<!-- begin field d097fa05-abf1-4b7a-892c-aa1400e80e58 --><h4>Common concerns</h4><!-- end field d097fa05-abf1-4b7a-892c-aa1400e80e58 -->","summary":null,"htmlStringContent":"<!-- begin item 82984b37-3274-4216-8ea0-aa1400e80e07 --><!-- begin field 334c38f0-fce9-4ddd-8029-aa1400e80e58 --><p><strong>Concerns reported by people who have recently had an MI may relate to:</strong></p><ul><li><strong>Resumption of normal daily activities</strong> <strong>and return to work:</strong><ul><li>After a myocardial infarction (MI), most people can return to their normal activities of daily living. The timing of resumption of normal activities depends on the person's physical and psychological status, as well as the type of activity.</li><li>Most people who have had an MI can safely return to work. When, and how, depends on the person's physical and psychological status, the nature of the work, and the work environment.</li></ul></li><li><strong>Safety to drive:</strong><ul><li>The latest information regarding medical fitness to drive can be obtained from the <a data-hyperlink-id=\"64a55dea-89c7-424a-920f-aa1400e7a4df\" href=\"https://www.gov.uk/government/publications/assessing-fitness-to-drive-a-guide-for-medical-professionals\">Driver and Vehicle Licensing Agency</a> (DVLA). In general:<ul><li>For a car or motorcycle licence holder, following an MI the person does not need to inform the DVLA. However, driving should stop for a time (the length depends on factors such as type of MI and treatments). The person should check with their insurer that they are still covered for driving.</li><li>For a bus, coach or lorry licence holder, following an MI the person must stop driving for a set period and inform the DVLA using form <a data-hyperlink-id=\"0d3c1e8c-bd23-4486-969f-a991002e4434\" href=\"https://www.gov.uk/government/publications/voch1-online-confidential-medical-information\">VOCH1</a>. Advise people that they can be fined if they continue to drive and do not inform the DVLA, and be prosecuted if involved in an accident.</li></ul></li></ul></li><li><strong>Resumption of sexual activity:</strong><ul><li>Sexual activity can be resumed when comfortable to do so, usually about four weeks after an MI.</li><li>Sexual activity presents no greater risk of triggering a subsequent MI in a person than if they had never had an MI.</li></ul></li><li><strong>Erectile dysfunction (ED):</strong><ul><li>Treatment of ED with a phosphodiesterase type 5 (PDE5) inhibitor (sildenafil, tadalafil or vardenafil) is usually effective and safe in men with stable CHD.<ul><li>A PDE5 inhibitor may be considered for people who have had an MI more than six months earlier, and who are now stable.</li><li>Avoid PDE5 inhibitors in people treated with nitrates and/or nicorandil, because this can lead to dangerously low blood pressure.</li><li>Nitrates (such as glyceryl trinitrate — GTN) should not be taken within 24 hours of taking sildenafil or vardenafil, or within 48 hours of taking tadalafil.</li><li>PDE5 inhibitors are not recommended for people with low blood pressure, severe heart failure (NYHA III–IV), refractory angina or recent cardiovascular events.</li></ul></li><li>Lifestyle and drug interventions including weight loss, exercise, smoking cessation, and statin treatment may also improve sexual function for some people.</li><li>For further information, see CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/erectile-dysfunction/\">Erectile dysfunction</a>.</li></ul></li><li><strong>Safety of air travel:</strong><ul><li>After an MI without complications, people who wish to travel by air should seek advice from the <a data-hyperlink-id=\"27922606-6abe-4333-8966-a991002e446b\" href=\"http://www.caa.co.uk/\">Civil Aviation Authority</a>.</li><li>People who have had a complicated MI may need expert individual advice.</li></ul></li><li><strong>Resumption of competitive sport:</strong><ul><li>Athletes who have had an MI should cease athletic training and competition until recovery is deemed complete. The duration before resuming sport depends on the severity of the cardiovascular event.</li><li>After the recuperation period, advice on competitive sport may need expert assessment of function and risk, and is dependent on the sport and the level of competitiveness.</li></ul></li></ul><!-- end field 334c38f0-fce9-4ddd-8029-aa1400e80e58 --><!-- end item 82984b37-3274-4216-8ea0-aa1400e80e07 -->","subChapters":[]},{"id":"f0f17ea4-bc43-5f6c-b29b-e09b9a58edb7","slug":"basis-for-recommendation-5b6","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 09fb1c87-ac8d-40ba-8f71-74556e71c4e3 --><h4>Basis for recommendation</h4><!-- end field 09fb1c87-ac8d-40ba-8f71-74556e71c4e3 -->","summary":null,"htmlStringContent":"<!-- begin item 5b6221e6-b07b-469d-a3ce-0f8c526d66f3 --><!-- begin field ce988e48-93f1-419d-9f7f-7feff8785c66 --><p>The information on management of a person who has had an MI is largely based on expert opinion in the National Institute of Health and Care Excellence (NICE) guidelines <em>Myocardial infarction: cardiac rehabilitation and prevention of further cardiovascular disease</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/mi-secondary-prevention/references/\">NICE, 2013</a>] and <em>Cardiovascular disease: risk assessment and reduction, including lipid modification</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/mi-secondary-prevention/references/\">NICE, 2016</a>].</p><h5>Salt intake</h5><ul><li>The European Society of Cardiology <em>Guidelines on the management of stable coronary artery disease </em>recommend the consumption of less than 6 g salt per day as part of a healthy diet for the secondary prevention of MI [<a class=\"bibliography-reference internal-reference\" href=\"/topics/mi-secondary-prevention/references/\">European Society of Cardiology, 2013</a>].</li></ul><h5>Alcohol</h5><ul><li>The recommendations to keep alcohol levels within recommended limits are based on expert opinion in the National Institute of Health and Care Excellence (NICE) guidelines <em>Myocardial infarction: cardiac rehabilitation and prevention of further cardiovascular disease</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/mi-secondary-prevention/references/\">NICE, 2013</a>]. However, since this NICE guideline was produced, the Department of Health have released new recommended low risk alcohol limits which CKS has therefore cited [<a class=\"bibliography-reference internal-reference\" href=\"/topics/mi-secondary-prevention/references/\">DH, 2016</a>].  </li></ul><h5>Influenza vaccination</h5><ul><li>The advice to offer people who have had an MI an annual influenza vaccine is in-line with Public Health England (PHE) guidance that states that people with ischaemic heart disease constitute an at-risk group [<a class=\"bibliography-reference internal-reference\" href=\"/topics/mi-secondary-prevention/references/\">PHE, 2018</a>].</li></ul><!-- end field ce988e48-93f1-419d-9f7f-7feff8785c66 --><!-- end item 5b6221e6-b07b-469d-a3ce-0f8c526d66f3 -->","subChapters":[]}]}]}}},"staticQueryHashes":["3666801979"]}